A Phase One Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism And Excretion Of [14C]PF-02341066 In Healthy Male Volunteers.

Trial Profile

A Phase One Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism And Excretion Of [14C]PF-02341066 In Healthy Male Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2012

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Neuroblastoma; Non-small cell lung cancer; Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 25 Oct 2011 Primary endpoints identified as reported by ClinicalTrials.gov.
    • 19 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Apr 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top